PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 21 filers reported holding PHARVARIS N V in Q2 2022. The put-call ratio across all filers is - and the average weighting 2.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $67,450,233 | +32.8% | 3,231,923 | 0.0% | 0.27% | +31.7% |
| Q2 2023 | $50,773,510 | +100.9% | 3,231,923 | 0.0% | 0.21% | +74.8% |
| Q1 2023 | $25,273,638 | -30.5% | 3,231,923 | 0.0% | 0.12% | -34.6% |
| Q4 2022 | $36,359,134 | +81.3% | 3,231,923 | +29.4% | 0.18% | +95.7% |
| Q3 2022 | $20,050,000 | -63.6% | 2,496,923 | +0.2% | 0.09% | -63.1% |
| Q2 2022 | $55,071,000 | +18.7% | 2,491,923 | +0.5% | 0.25% | +34.0% |
| Q1 2022 | $46,382,000 | +19.4% | 2,480,319 | +1.0% | 0.19% | +67.9% |
| Q4 2021 | $38,847,000 | -5.8% | 2,455,536 | +2.7% | 0.11% | -0.9% |
| Q3 2021 | $41,254,000 | -5.1% | 2,391,517 | 0.0% | 0.11% | -14.4% |
| Q2 2021 | $43,454,000 | -36.0% | 2,391,517 | -1.2% | 0.13% | -34.7% |
| Q1 2021 | $67,910,000 | – | 2,420,155 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,743,450 | $78,125,802 | 43.39% |
| venBio Partners LLC | 4,264,672 | $89,003,705 | 25.24% |
| Bain Capital Life Sciences Investors, LLC | 4,784,674 | $99,856,146 | 11.17% |
| 5AM Venture Management, LLC | 587,600 | $12,263,212 | 3.53% |
| VR Adviser, LLC | 1,563,513 | $32,630,516 | 3.44% |
| Novo Holdings A/S | 1,329,325 | $27,743,013 | 2.05% |
| Cormorant Asset Management, LP | 1,361,460 | $28,413,670 | 1.66% |
| GENERAL ATLANTIC, L.P. | 4,406,252 | $91,958,479 | 1.42% |
| Foresite Capital Management V, LLC | 33,142 | $691,674 | 1.10% |
| Soleus Capital Management, L.P. | 343,975 | $7,178,758 | 0.66% |